Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:

NCT ID: NCT00370539 Recruiting - Clinical trials for Neovascular Age-Related Macular Degeneration

Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD

Start date: September 2006
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular AMD.

NCT ID: NCT00370370 Active, not recruiting - Clinical trials for Neovascular Age-Related Macular Degeneration

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Start date: November 2005
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

NCT ID: NCT00344227 Completed - Clinical trials for Neovascular Age-Related Macular Degeneration

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging. OCT was then used to determine the need for retreatment after 3 monthly injections of Lucentis. Patients would be followed for 2 years.

NCT ID: NCT00327470 Terminated - Clinical trials for Macular Degeneration

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD

PERSPECTIVES
Start date: July 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.

NCT ID: NCT00320788 Completed - Clinical trials for Macular Degeneration

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Start date: April 2006
Phase: Phase 2
Study type: Interventional

This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD. The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.

NCT ID: NCT00320775 Completed - Clinical trials for Macular Degeneration

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.

NCT ID: NCT00305630 Completed - Clinical trials for Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

Start date: July 2002
Phase: Phase 2/Phase 3
Study type: Interventional

Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD). Patients undergoing PDT are randomized to either a periocular corticosteroid injection with 40 mg of triamcinolone acetonide or observation just prior to PDT. Patients are followed for 6 months. Primary outcome is leakage from choroidal neovascularization (CNV) at 3 months on fluorescein angiography.

NCT ID: NCT00299507 Completed - Clinical trials for Macular Degeneration

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Start date: March 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).

NCT ID: NCT00215670 Completed - Clinical trials for Age-Related Macular Degeneration

Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)

Start date: November 2002
Phase: Phase 2/Phase 3
Study type: Interventional

The objectives of this study are to characterize the safety, tolerability and pharmacokinetics of pegaptanib when given as 1 or 3mg/eye intravitreous injections every 6 weeks for 54 weeks in patients with subfoveal choroidal neovascularization (CNV) secondary to AMD.

NCT ID: NCT00211419 Completed - Clinical trials for Maculopathy, Age-Related

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).